<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00423280</url>
  </required_header>
  <id_info>
    <org_study_id>06/Q1604/114</org_study_id>
    <nct_id>NCT00423280</nct_id>
  </id_info>
  <brief_title>Effect of 6R-BH4 Treatment in Coronary Artery Disease (OXBIO Study)</brief_title>
  <official_title>A Randomised, Placebo-Controlled Study of Two Doses of Oral 6R-BH4 on Vascular Function in Subjects With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of 6R-BH4 on vascular function in
      patients with coronary artery disease. We hypothesize that 6R-BH4 will improve vascular
      function in these patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Decreased production of nitric oxide (NO) from the endothelium (the layer of cells that forms
      the lining of all blood vessels) has been shown to contribute to atherosclerosis. NO has
      multiple beneficial effects on vascular function. Endothelial function can be measured in
      humans via a number of methods, and endothelial dysfunction has been shown to be a strong
      adverse predictor of cardiovascular events and mortality.

      Tetrahydrobiopterin (BH4) is essential for the production of NO in endothelial cells. 6R-BH4
      is a synthetic version of naturally occurring BH4. We aim to investigate the effects of oral
      6R-BH4 supplementation on endothelial function in patients with coronary artery disease.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2006</start_date>
  <completion_date type="Anticipated">February 2009</completion_date>
  <primary_completion_date type="Anticipated">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular function using non-invasive magnetic resonance imaging (MRI).</measure>
    <time_frame>Pre- and post- treatment with 6R-BH4 or placebo</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laboratory measures of vascular function.</measure>
    <time_frame>At time of CABG surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>700mg/day 6R-BH4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400mg/day 6R-BH4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6R-BH4</intervention_name>
    <description>6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>Sapropterin dihydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Multi-vessel coronary artery disease scheduled for coronary artery bypass surgery
             (CABG)

        Exclusion Criteria:

          -  Inability to provide informed consent

          -  Female subject who is pregnant, lactating or planning pregnancy during course of study

          -  Prior clinical diagnosis of heart failure requiring diuretic therapy with evidence of
             severe left ventricular dysfunction

          -  Recent acute coronary event (&lt;4 weeks)

          -  Emergency CABG

          -  Newly diagnosed diabetes mellitus (&lt;1 month)

          -  Body weight &gt;130kg

          -  Impaired renal function (creatinine &gt;180umol/l)

          -  Elevated liver function tests (ALT &gt;50umol/l or AST &gt;2x normal)

          -  Pacemakers, ICDs or metallic implants not compatible with MRI scanning

          -  Subjects receiving experimental medications or participating in another study

          -  Terminally ill subjects

          -  Known hypersensitivity to 6R-BH4

          -  Concomitant treatment with methotrexate, levodopa, PDE-3 or PDE-5 inhibitors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith M Channon, MD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Colin Cunnington, MBChB MRCP</last_name>
    <phone>+44-1865-221866</phone>
    <email>colin.cunnington@cardiov.ox.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiovascular Medicine, University of Oxford</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2007</study_first_submitted>
  <study_first_submitted_qc>January 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2007</study_first_posted>
  <last_update_submitted>August 6, 2008</last_update_submitted>
  <last_update_submitted_qc>August 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>Mrs Heather House</name_title>
    <organization>University of Oxford</organization>
  </responsible_party>
  <keyword>Endothelium</keyword>
  <keyword>Nitric Oxide</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Tetrahydrobiopterin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

